Literature DB >> 6198439

Monoclonal antibodies reactive with the surface and secreted glycoproteins of Marek's disease virus and herpesvirus of turkeys.

K Ikuta, S Ueda, S Kato, K Hirai.   

Abstract

Hybridomas were formed between mouse myeloma cells and spleen cells from mice immunized with Marek's disease virus (MDV) or with herpesvirus of turkeys (HVT). Three monoclonal antibodies were obtained, two (M26 and M34) from MDV clones and one (H9) from an HVT clone, all of which were specific for cross-reactive membrane antigen (MA) expressed on the surface of cells infected with MDV or HVT. All three antibodies also reacted with MDV- and HVT-specific glycoproteins in the molecular weight (mol. wt.) ranges 54K to 70K (MDV-gp54/70) and 50K to 64K (HVT-gp50/64), respectively. These glycoproteins constitute the putative 'A' antigens which are found in the medium of cultures infected with MDV or HVT. These results suggest that the cross-reactive MA may correspond to 'A' antigen. Pulse-chase experiments using monoclonal antibodies revealed the presence in virus-infected cells of precursor and processed forms of MDV-gp54/70 and HVT-gp50/64 which differ in size. Moreover, by two-dimensional gel electrophoresis we found that MDV and HVT glycoproteins were separated to heterogeneous spots by electric charge as well as mol. wt. The several spots with higher mol. wt. and with more acidic isoelectric points among them were lost by treatment with neuraminidase, suggesting that the processing was, at least in part, due to the addition of sialic acid to the precursor forms. Tunicamycin blocked the surface expression of cross-reactive HVT-MA on HVT-infected cells. Phosphonoacetic acid inhibited both the appearance of HVT-MA on the cell surface and synthesis of HVT-gp50/64, indicating that the MA and secreted glycoprotein were late gene products of the HVT genome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6198439     DOI: 10.1099/0022-1317-64-12-2597

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  21 in total

1.  Marek's disease virus expresses multiple UL44 (gC) variants through mRNA splicing that are all required for efficient horizontal transmission.

Authors:  Keith W Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

2.  Identification of the gene encoding Marek's disease herpesvirus A antigen.

Authors:  R J Isfort; H J Kung; L F Velicer
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

3.  Amplification of a tandem direct repeat within inverted repeats of Marek's disease virus DNA during serial in vitro passage.

Authors:  K Maotani; A Kanamori; K Ikuta; S Ueda; S Kato; K Hirai
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

4.  Synthesis, processing, and secretion of the Marek's disease herpesvirus A antigen glycoprotein.

Authors:  R J Isfort; R A Stringer; H J Kung; L F Velicer
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

5.  Identification with monoclonal antibodies of virus-specific DNA-binding proteins in the nuclei of cells infected with three serotypes of Marek's disease virus-related viruses.

Authors:  K Nakajima; K Ikuta; S Ueda; S Kato; K Hirai
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

6.  Monospecific antibodies to Marek's disease virus antigen B dimer (200 kDa) and monomer (130 and 60 kDa) glycoproteins neutralize virus infectivity and detect the antigen B proteins in infected cell membranes.

Authors:  I Davidson; Y Becker; M Malkinson
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

7.  Similarities and dissimilarities in the structure and expression of viral genomes of various virus strains immunologically related to Marek's disease virus.

Authors:  K Hirai; K Nakajima; K Ikuta; R Kirisawa; Y Kawakami; T Mikami; S Kato
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

8.  Detection of phosphorylated forms of Moloney murine leukemia virus major capsid protein p30 by immunoprecipitation and two-dimensional gel electrophoresis.

Authors:  K Ikuta; R B Luftig
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

9.  Comparison of the sequence of the secretory glycoprotein A (gA) gene in Md5 and BC-1 strains of Marek's disease virus type 1.

Authors:  T Ihara; A Kato; S Ueda; A Ishihama; K Hirai
Journal:  Virus Genes       Date:  1989-11       Impact factor: 2.332

10.  Antigen B of the vaccine strains of Marek's disease virus and herpesvirus of turkeys presents heat-labile group and serotype specific epitopes.

Authors:  M Malkinson; I Davidson; Y Becker
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.